Introduction {#s1}
============

Colorectal cancer (CRC) represents more than 1,849,518 new cases, accounting for approximately 10.2% of all neoplasms worldwide ([@B1]). CRC is the third most common neoplasm in men and the second in women ([@B1]--[@B4]). CRC mortality is also high, with 880,792 deaths having been estimated for 2018, corresponding to 9.2% of the total, with higher rates (52%) being observed in less developed regions of the world ([@B1]). The incidence of CRC varies more than 10-fold worldwide ([@B1]). The highest detection rates are observed in Australia, New Zealand, and countries of Europe and North America, and the lowest are found in the countries of Africa, South America, and Asia ([@B1], [@B2]). In Brazil, according to the National Cancer Institute (INCA), an estimated 17,380 new cases of colon and rectum cancer in men and 18,980 in women are expected for 2018, which occupies the third position in men and the second among women ([@B4]).

Several reasons account for these discrepancies, including distinct risk factors. Age is the primary risk factor, yet many other factors contribute to CRC development including a previous history of colorectal neoplasia and/or adenomas or family history of CRC; a diet rich in red meat and saturated fats, fruits, and vegetables; obesity and sedentary lifestyle; smoking; diabetes mellitus; CRC-associated syndromes such as familial adenomatous polyposis, hereditary non-polyposis colorectal cancer (HNPCC or Lynch syndrome); and inflammatory diseases of the colon ([@B2], [@B3], [@B5], [@B6]). Besides the risk factors abovementioned, patient ethnicity has been reported as a risk and prognostic factor ([@B7]--[@B12]). The ethnic structure becomes more pressing in the Brazilian population due to its great admixture ([@B13]--[@B17]). Currently, genetic markers are available that determine, with more assertiveness than the self-declared form or based on physical traits, the ethnic structure of each individual ([@B14], [@B18]).

Despite the high incidence and mortality rate of CRC in Brazil, few studies have comprehensively described and characterized the main clinicopathological features of Brazilian patients with CRC ([@B19], [@B20]). Therefore, this study aimed to characterize the clinicopathological aspects of CRC patients, to determine their genetic ancestry, and to identify whether the genetic ancestry can influence patients\' clinicopathological features and disease outcome.

Methods {#s2}
=======

Study Design and Data Source
----------------------------

We conducted a retrospective observational cohort study enrolling 1,002 patients with CRC admitted from 2000 to 2014 at Barretos Cancer Hospital, Barretos, São Paulo, Brazil. Of the total of 1,002 cases, 96.3% (965/1,002) were selected from the Department of Low-Digestive and 3.7% (37/1,002) were oncogenetic-based cases, being 1.8% (18/1,002) confirmed Lynch syndrome cases, 1.5% (15/1,002) confirmed familial adenomatous polyposis (FAP) syndrome cases, and 0.4% (4/1,002) of unclassified hereditary syndrome ([@B21]). Clinicopathological and treatment data of CRC patients were collected from patient medical records. The present study evaluated 21 variables. The seventh edition of the American Joint Committee on Cancer (AJCC) was used for tumor staging. The Institutional Ethics Committee approved the study (protocol number: 600/2012-CAAE: 02468812.30000.5437).

Genetic Ancestry Determination
------------------------------

DNA samples were recovered from formalin-fixed paraffin-embedded (FFPE) tissue of tumor specimens obtained from surgical or endoscopic procedures. The DNA was isolated using the DNA Micro kit (Qiagen), according to the method previously established by our group ([@B22]).

The ancestry of the patients was determined using ancestry informative markers (AIMs) as previously reported ([@B14], [@B23]--[@B25]). Briefly, 46 small insertion--deletion (INDEL) polymorphisms were ascertained to maximize the divergence between four human major population groups: Amerindian (AME), European (EUR), African (AFR), and East Asian (ASN). These markers were selected due to their high allele frequency divergence between different ancestral or geographically distant populations, including more than 1,000 individuals from 40 reference populations from the Human Genome Diversity Project (HGDP)-Centre d/Etude du Polymorphisme (CEPH), plus individuals from Angola, Portugal, Taiwan, and indigenous Brazilian, which allowed to establish the ancestral proportions in high admixture individuals and populations, like the Brazilian one ([@B14]). Moreover, they were assembled in a simple multiplex reaction following a short amplicon strategy, adequate for challenging samples such as FFPE ([@B15], [@B26], [@B27]). The primer sequences and PCR conditions were according to Giolo et al. ([@B14]).

After DNA extraction, and multiplex PCR with 46 primers, the amplified products were further subjected to capillary electrophoresis and fragment analysis on an ABI 3500 Genetic Analyzer (Applied Biosystems) according to the manufacturer\'s instructions. These 46 INDELs are used mainly to estimate ancestry proportions in admixed populations and assess the structure of those populations. Two observers independently analyzed the electropherograms, and the genotypes were automatically assigned with GeneMapper Software v4.1 (Applied Biosystems).

The ancestry ratios were evaluated using the Structure Software v2.3.4 ([@B23], [@B24], [@B28], [@B29]), considering the four main population groups, AME, EUR, AFR, and ASN, as possible contributors to the current Brazilian genetic composition. Briefly, the data available for the HGDP-CEPH panel were used as a reference for the ancestral populations, and a supervised analysis was performed to estimate ancestry relationship proportions of the individuals involved in the study. The Structure software runs considering K = 4 consisted of 100,000 burning steps followed by 100,000 Markov Chain Monte Carlo iterations. The option "Use population information to test for migrants" was used with the admixture model, considering allele frequencies correlated, and updating allele frequencies using only individuals with POPFLAG = 1.

Statistical Analyses
--------------------

Patient and cancer characteristics were reported as frequencies (number and percentage). First, the continuous variables of genetic ancestry component were summarized as mean \[standard deviation (SD)\]. For the association of the genetic ancestry component (AFR, EUR, ASN, AME) by AIMs panel with patient and clinical characteristics, the chi-square test or Fisher\'s exact test was used. For this step, ancestry proportions were further categorically defined as low, intermediate, and high based on tercile distribution ([Table 1](#T1){ref-type="table"} and [Supplementary Table 1](#SM3){ref-type="supplementary-material"}).

###### 

Ancestry background categorization according to tercile based on percentage proportions for all four ethnic groups.

  **Ancestry components**   **Low**   **Intermediate**   **High**
  ------------------------- --------- ------------------ ----------
  AFR                       \<0.030   0.030--0.120       \>0.120
  EUR                       \<0.710   0.710--0.870       \>0.870
  ASN                       \<0.030   0.030--0.050       \>0.050
  AME                       \<0.030   0.030--0.060       \>0.060

The overall survival (OS) and the cancer-specific survival (CSS) rates were obtained using the Kaplan--Meier method. Survival rates were estimated in months. Survival was defined as the period from diagnosis to the date of death or the time at which information was last obtained. For the analysis, the event of interest was death by any cause for OS and death related to cancer for CSS. Cases that were alive were censored for OS, and cases that were alive or dead from other causes were censored for CSS. Such information was obtained through direct consultation to the death certificate or medical records. The follow-up median of our sample was 62.0 months. The log-rank test was used to compare survival curves, and results were considered significant when the *p* \< 0.05.

Multiple confirmatory models were used to check whether genetic ancestry component (AFR, EUR, ASN, AME) by AIMs panel was related to the prognosis of CRC. Multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the variables with *p* \< 0.20 in univariate analyses and adjusted with treatment period and genetic ancestry components by AIMs panel. Fisher exact test was used for association analysis.

For tabulation and statistical analysis, the IBM® SPSS® Statistics 21.0 software for Windows (IBM Corporation, Route 100, Somers, NY 10589) was used. The level of statistical significance was set at 0.05 for all analyses.

Results {#s3}
=======

Clinicopathological Features
----------------------------

The present study included 1,002 cases, and the main clinicopathological features are summarized in [Table 2](#T2){ref-type="table"}. A detailed description of therapeutic regimens is shown in [Supplementary Table 2](#SM3){ref-type="supplementary-material"}. There were more men than women in the population (51.9%), most patients were between 50 and 75 years old at diagnosis (60.5%), and the majority lived in the South or Southeast regions of Brazil (82%). The distribution of the CRC patients according to the Brazilian state of origin is plotted in [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}. The left colon was the leading primary tumor site, representing 46% of the cases, and adenocarcinoma was the main histological type, representing 93.5% of the cases. The cases were distributed in all stages, but clinical stages II and III were the most common, representing together 70.8% of the cases.

###### 

Clinicopathological features of Brazilian colorectal cancer patients (*n* = 1,002).

  **Variable**                  **Categories**            ***n***   **%**
  ----------------------------- ------------------------- --------- -------
  Gender                        Male                      520       51.9
                                Female                    482       48.1
  Age at diagnose               \<50                      290       28.9
  (in years)                    \>= 50 to \<75            606       60.5
                                \>= 75                    106       10.6
  Brazilian region of origin    South / Southeast         822       82.0
                                Midwest                   87        8.7
                                North / Northeast         93        9.3
  Primary tumor site            Right colon               250       25.0
                                Left colon                466       46.5
                                Rectum                    285       28.5
                                Missing data              1         
  Clinical stage (AJCC)         0/I                       125       12.5
                                II                        376       37.6
                                III                       332       33.2
                                IV                        167       16.7
                                Missing data              2         
  Histological type             Adenocarcinoma            937       93.5
                                Mucinous                  58        5.8
                                Others                    7         0.7
  Histological grade            I / II                    924       93.6
                                III / Undifferentiated    63        6.4
                                Missing data              15        
  Lymphovascular invasion       No                        621       67.4
                                Yes                       300       32.6
                                Missing data              81        
  Perineural invasion           No                        731       85.6
                                Yes                       123       14.4
                                Missing data              148       
  Presence synchronous tumors   No                        944       94.2
                                Yes                       58        5.8
  Presence of recurrence        No                        698       69.7
                                Yes                       304       30.3
  Treatment period              2000--2009                184       18.4
                                2010--2014                818       81.6
  Surgery                       No                        40        4.0
                                Yes                       961       96.0
                                Missing data              1         
  Neoadjuvant chemotherapy      No                        18        10.2
                                Yes                       159       89.8
                                Not applicable            824       
                                Missing data              1         
  Adjuvant chemotherapy         No                        543       55.1
                                Yes                       442       44.9
                                Missing data                        
  Radiotherapy                  No                        793       79.1
                                Yes, neoadjuvant          165       16.5
                                Yes, adjuvant             21        2.1
                                Yes, paliative            21        2.1
                                Missing data              2         
  Vital status                  Alive without cancer      465       46.4
                                Alive with cancer         48        4.8
                                Death for cancer          422       42.1
                                Death for others causes   67        6.7

Genetic Ancestry
----------------

The present study also aimed to evaluate the genetic ancestry of the patients, which was performed in 934/1,002 (93.2%) of the cases. In a small subset of cases (*n* = 68), the genetic ancestry could not be evaluated due to low quantity and poor-quality DNA. We observed a great admixture in genetic composition, with the following averages of ancestral proportions: AFR 12.7% (SD = 15.7%), EUR 74.2% (SD = 20.6%), ASN 6.5% (SD = 11.3%), and AME 6.6% (SD = 7.1%) ([Figure 1](#F1){ref-type="fig"}). The average of each genetic ancestry component according to the Brazilian state of origin is plotted in [Figure 2](#F2){ref-type="fig"}. The ancestry proportions were further categorically defined as low, intermediate, and high based on tercile distribution ([Table 1](#T1){ref-type="table"} and [Supplementary Table 1](#SM3){ref-type="supplementary-material"}).

![Individual ancestry estimates for the Brazilian colorectal cancer patients (*n* = 934).](fonc-10-00145-g0001){#F1}

![Average of each genetic ancestry component according to the Brazilian state of origin. AFR- African; EUR- European; ASN- Asian; AME- Amerindian (Native American).](fonc-10-00145-g0002){#F2}

We further investigated the association of genetic ancestry with patients\' clinicopathological characteristics ([Table 3](#T3){ref-type="table"}). We observed significant associations between the AFR component and younger age at diagnosis (*p* = 0.013), Brazilian region of origin (*p* \< 0.001), and recurrence of the disease (*p* = 0.034). For the EUR component, we found significant associations with the region of origin (*p* \< 0.001), adenocarcinoma (*p* = 0.023), higher histological grade (*p* = 0.040), and presence of synchronous tumors (*p* = 0.012). For the AME component, a significant association with the mucinous histological type (*p* = 0.033) was observed.

###### 

Association between clinicopathological and genetic ancestry components by AIM-INDEL panel (*n* = 934).

  **Variable/Categories**           **AFR**      **EUR**      **ASN**      **AME**                                                                                                                                                  
  --------------------------------- ------------ ------------ ------------ ------------- ------------ ------------ ------------ ------------- ------------ ------------ ------------ ------- ------------ ------------ ------------ -----------
  **GENDER**                                                                                                                                                                                                                        
  Male                              189 (54.5)   153 (55.2)   149 (48.1)   0.149         155 (49.1)   174 (55.2)   162 (53.5)   0.277         234 (52.6)   114 (55.6)   143 (50.4)   0.517   212 (52.5)   123 (53.2)   156 (52.2)   0.969
  Female                            158 (45.5)   124 (44.8)   161 (51.9)                 161 (50.9)   141 (44.8)   141 (46.5)                 211 (47.4)   91 (44.4)    141 (49.6)           192 (47.5)   108 (46.8)   143 (47.8)   
  **AGE AT DIAGNOSE (IN YEARS)**                                                                                                                                                                                                    
  \<50                              74 (21.4)    87 (31.4)    96 (31.0)    **0.013**     99 (31.3)    82 (26.0)    76 (25.1)    0.453         115 (25.8)   59 (28.8)    83 (29.2)    0.528   118 (29.2)   59 (25.6)    80 (26.8)    0.701
  ≥50 to \<75                       225 (64.8)   164 (59.2)   185 (59.7)                 185 (58.5)   198 (62.9)   191 (63.1)                 275 (61.8)   129 (62.9)   170 (59.9)           240 (59.4)   150 (64.9)   184 (61.5)   
  ≥75                               48 (13.8)    26 (9.4)     29 (9.3)                   32 (10.2)    35 (11.1)    36 (11.8)                  55 (12.4)    17 (8.3)     31 (10.9)            46 (11.4)    22 (9.5)     35 (11.7)    
  **BRAZILIAN REGION OF ORIGIN**                                                                                                                                                                                                    
  South/Southeast                   308 (88.8)   226 (81.6)   232 (74.8)   **\<0.001**   237 (75.0)   262 (83.2)   267 (88.1)   **\<0.001**   369 (82.9)   163 (79.5)   234 (82.4)   0.160   346 (85.6)   187 (81.0)   233 (78.0)   0.052
  Midwest                           25 (7.2)     32 (11.6)    28 (9.1)                   32 (10.1)    27 (8.6)     26 (8.5)                   42 (9.5)     15 (7.3)     28 (9.9)             34 (8.5)     21 (9.0)     30 (10.0)    
  North/Northeast                   14 (4.0)     19 (6.8)     50 (16.1)                  47 (14.9)    26 (8.3)     10 (3.3)                   34 (7.6)     27 (13.2)    22 (7.7)             24 (5.9)     23 (10.0)    36 (12.0)    
  **PRIMARY TUMOR SITE**                                                                                                                                                                                                            
  Right colon                       76 (22.0)    77 (27.8)    84 (27.1)    0.331         77 (24.4)    88 (27.9)    72 (23.8)    0.178         119 (26.7)   49 (24.0)    69 (24.3)    0.417   103 (25.6)   62 (26.8)    72 (24.1)    0.335
  Left colon                        171 (49.4)   125 (45.1)   133 (42.9)                 136 (43.0)   140 (44.5)   153 (50.7)                 211 (47.5)   95 (46.6)    123 (43.3)           197 (48.8)   102 (44.2)   130 (43.5)   
  Rectum                            99 (28.6)    75 (27.1)    93 (30.0)                  103 (32.6)   87 (27.6)    77 (25.5)                  115 (25.8)   60 (29.4)    92 (32.4)            103 (25.6)   67 (29.0)    97 (32.4)    
  **CLINICAL STAGE (AJCC)**                                                                                                                                                                                                         
  0/I                               47 (13.6)    37 (13.4)    36 (11.6)    0.580         36 (11.4)    42 (13.4)    42 (13.8)    0.833         60 (13.5)    27 (13.2)    33 (11.7)    0.540   51 (12.7)    29 (12.6)    40 (13.4)    0.877
  II                                129 (37.3)   112 (40.6)   114 (36.8)                 118 (37.3)   122 (38.9)   115 (38.1)                 172 (38.7)   74 (36.1)    109 (38.5)           157 (39.0)   89 (38.5)    109 (36.6)   
  III                               108 (31.2)   92 (33.3)    106 (34.2)                 114 (36.1)   97 (30.9)    95 (31.5)                  150 (33.8)   62 (30.2)    94 (33.2)            136 (33.7)   70 (30.3)    100 (33.6)   
  IV                                62 (17.9)    35 (12.7)    54 (17.4)                  48 (15.2)    53 (16.8)    50 (16.6)                  62 (14.0)    42 (20.5)    47 (16.6)            59 (14.6)    43 (18.6)    49 (16.4)    
  **HISTOLOGICAL TYPE**                                                                                                                                                                                                             
  Adenocarcinoma                    325 (93.6)   261 (94.2)   285 (91.9)   0.429         294 (93.0)   286 (90.8)   291 (96.0)   **0.023**     418 (93.9)   191 (93.2)   262 (92.3)   0.429   382 (94.6)   219 (94.8)   270 (90.3)   **0.033**
  Mucinous                          19 (5.5)     13 (4.7)     24 (7.8)                   22 (7.0)     24 (7.6)     10 (3.3)                   24 (5.4)     14 (6.8)     18 (6.3)             19 (4.7)     9 (3.9)      28 (9.4)     
  Others                            3 (0.9)      3 (1.1)      1 (0.3)                    0 (0.0)      5 (1.6)      2 (0.7)                    3 (0.7)      0 (0.0)      4 (1.4)              3 (0.7)      3 (1.3)      1 (0.3)      
  **HISTOLOGICAL GRADE**                                                                                                                                                                                                            
  I/II                              317 (93.0)   259 (94.9)   285 (93.4)   0.612         298 (95.8)   282 (91.0)   281 (94.3)   **0.040**     404 (92.4)   193 (95.1)   264 (94.6)   0.332   374 (94.4)   214 (93.0)   273 (93.2)   0.713
  III/Undifferentiated              24 (7.0)     14 (5.1)     20 (6.6)                   13 (4.2)     28 (9.0)     17 (5.7)                   33 (7.6)     10 (4.9)     15 (5.4)             22 (5.6)     16 (7.0)     20 (6.8)     
  **LYMPHOVASCULAR INVASION**                                                                                                                                                                                                       
  No                                211 (64.7)   186 (71.0)   195 (69.9)   0.209         212 (73.1)   189 (64.5)   191 (67.3)   0.075         282 (67.8)   127 (69.0)   183 (68.5)   0.951   258 (68.4)   138 (64.8)   196 (70.8)   0.370
  Yes                               115 (35.3)   76 (29.0)    84 (30.1)                  78 (26.9)    104 (35.5)   93 (32.7)                  134 (32.2)   57 (31.0)    84 (31.5)            119 (31.6)   75 (35.2)    81 (29.2)    
  **PERINEURAL INVASION**                                                                                                                                                                                                           
  No                                252 (84.8)   208 (84.6    230 (87.1)   0.657         235 (86.4)   234 (84.5)   221 (85.7)   0.812         327 (85.8)   152 (87.9)   211 (83.4)   0.425   299 (86.2)   171 (83.4)   220 (86.3)   0.617
  Yes                               45 (15.2)    38 (15.4)    34 (12.9)                  37 (13.6)    43 (15.5)    37 (14.3)                  54 (14.2)    21 (12.1)    42 (16.6)            48 (13.8)    34 (16.6)    35 (13.7)    
  **PRESENCE SYNCHRONOUS TUMORS**                                                                                                                                                                                                   
  No                                332 (95.7)   260 (93.9)   285 (91.9)   0.135         288 (91.1)   305 (96.8)   284 (93.7)   **0.012**     417 (93.7)   196 (95.6)   264 (93.0)   0.469   381 (94.3)   211 (91.3)   285 (95.3)   0.149
  Yes                               15 (4.3)     17 (6.1)     25 (8.1)                   28 (8.9)     10 (3.2)     19 (6.3)                   28 (6.3)     9 (4.4)      20 (7.0)             23 (5.7)     20 (8.7)     14 (4.7)     
  **PRESENCE OF RECURRENCE**                                                                                                                                                                                                        
  No                                238 (68.6)   188 (67.9)   237 (76.5)   **0.034**     232 (73.4)   217 (68.9)   214 (70.6)   0.450         311 (69.9)   144 (70.2)   208 (73.2)   0.602   286 (70.8)   170 (73.6)   207 (69.2)   0.544
  Yes                               109 (31.4)   89 (32.1)    73 (23.5)                  84 (26.6)    98 (31.1)    89 (29.4)                  134 (30.1)   61 (29.8)    76 (26.8)            118 (29.2)   61 (26.4)    92 (30.8)    

*Significant associations are indicated in bold*.

Survival Analysis
-----------------

An initial univariate analysis of survival was performed, including 1,002 individuals: 489 events occurred in OS, and 422 events occurred in CSS. The probability of patients living for more than 5 years was 58.2% for OS and 62.3% for CSS ([Table 4](#T4){ref-type="table"}). Several significant associations were observed between OS and CSS and patients\' features, including gender, clinical stage, histological type, histological grade, lymphovascular invasion, perineural invasion, presence of recurrence, treatment period, neoadjuvant chemotherapy, adjuvant chemotherapy, and radiotherapy ([Table 3](#T3){ref-type="table"} and [Supplementary Figure 2](#SM2){ref-type="supplementary-material"}). On the univariate survival analyses (OS and CSS), the genetic ancestry categorically defined as low, intermediate, and high based on terciles was not associated with CRC survival ([Table 4](#T4){ref-type="table"}).

###### 

Kaplan-Meier estimates of overall survival and cancer-specific survival of colorectal cancer patients (*n* = 1,002).

  **Variable**                 **Categories**         **Cases**   **Global survival**   **Cancer-specific survival**                              
  ---------------------------- ---------------------- ----------- --------------------- ------------------------------ ------------- ----- ------ -------------
  All cases                                           1,002       489                   58.2                                         422   62.3   
  Gender                       Male                   520         275                   54.4                           **0.004**     236   58.9   **0.011**
                               Female                 482         214                   62.3                                         186   65.8   
  Age at diagnose              \<50                   290         134                   62.0                           0.066         133   62.4   0.368
  (in years)                   ≥50 to \<75            606         299                   57.0                                         257   61.4   
                               ≥75                    106         56                    55.0                                         32    67.7   
  Brazilian region of origin   South / Southeast      822         405                   57.9                           0.514         352   61.7   0.609
                               Midwest                87          37                    65.3                                         32    69.8   
                               North / Northeast      93          47                    54.0                                         38    59.9   
  Primary tumor site           Right colon            250         111                   60.0                           0.289         90    65.7   0.168
                               Left colon             466         221                   58.9                                         195   62.2   
                               Rectum                 285         156                   55.6                                         136   59.6   
  Clinical stage (AJCC)        0/I                    125         29                    86.4                           **\<0.001**   15    93.9   **\<0.001**
                               II                     376         126                   72.5                                         97    78.2   
                               III                    332         175                   54.4                                         156   57.8   
                               IV                     167         157                   13.6                                         154   13.9   
  Histological type            Adenocarcinoma         937         458                   58.5                           **0.004**     395   62.6   **0.009**
                               Mucinous               58          25                    60.1                                         22    62.2   
                               Others                 7           6                     14.3                                         5     17.1   
  Histological grade           I/II                   924         441                   59.6                           **0.001**     380   63.7   **0.002**
                               III/Undifferentiated   63          41                    37.4                                         35    41.1   
  Lymphovascular               No                     621         227                   69.7                           **\<0.001**   180   74.9   **\<0.001**
  invasion                     Yes                    300         200                   40.6                                         184   42.8   
  Perineural invasion          No                     731         301                   64.9                           **\<0.001**   248   69.8   **\<0.001**
                               Yes                    123         89                    35.4                                         85    36.0   
  Presence synchronous         No                     944         463                   58.2                           0.967         403   62.1   0.487
  tumors                       Yes                    58          26                    58.6                                         19    65.3   
  Presence of recurrence       No                     698         245                   67.8                           **\<0.001**   182   74.2   **\<0.001**
                               Yes                    304         244                   36.5                                         240   36.9   
  Treatment period             2000--2009             184         142                   49.5                           **\<0.001**   138   50.2   **\<0.001**
                               2010--2014             818         347                   60.3                                         284   65.3   
  Surgery                      No                     40          38                    7.5                            **\<0.001**   37    7.7    **\<0.001**
                               Yes                    961         450                   60.4                                         385   64.6   
  Neoadjuvant chemotherapy     No                     18          14                    38.9                           **0.002**     10    46.7   **0.034**
                               Yes                    159         80                    59.1                                         71    62.7   
  Adjuvant chemotherapy        No                     543         313                   49.4                           **\<0.001**   260   54.6   **\<0.001**
                               Yes                    442         169                   69.1                                         157   71.0   
  Radiotherapy                 No                     793         376                   58.6                           **\<0.001**   322   62.8   **\<0.001**
                               Yes, neoadjuvant       165         85                    58.7                                         73    63.0   
                               Yes, adjuvant          21          7                     81.0                                         7     81.0   
                               Yes, paliative         21          20                    19.0                                         20    19.0   
  AFR                          Low                    347         171                   58.0                           0.403         148   62.2   0.308
                               Intermediate           277         139                   56.7                                         119   60.8   
                               High                   310         137                   60.2                                         114   64.9   
  EUR                          Low                    316         140                   61.3                           0.247         117   66.0   0.228
                               Intermediate           315         160                   55.0                                         136   59.1   
                               High                   303         147                   58.8                                         128   63.0   
  ASN                          Low                    445         215                   57.6                           0.833         184   62.1   0.819
                               Intermediate           205         101                   59.2                                         86    63.2   
                               High                   284         131                   58.8                                         111   63.3   
  AME                          Low                    404         190                   58.9                           0.859         167   63.0   0.949
                               Intermediate           231         109                   58.7                                         95    61.6   
                               High                   299         148                   57.2                                         119   63.2   

*Significant associations are indicated in bold*.

The multivariate analysis for CSS adjusted by treatment period and genetic ancestry components showed that clinical stage, lymphovascular invasion, and the presence of recurrence were associated with an increased relative risk of death from cancer (p \< 0.05), whereas adjuvant chemotherapy was associated with a lower risk of death ([Table 5](#T5){ref-type="table"}). These results are explained by the different therapeutic approaches used in distinct clinical stages ([Supplementary Tables 3](#SM3){ref-type="supplementary-material"}, [4](#SM3){ref-type="supplementary-material"}).

###### 

Multivariate analysis of cancer-specific survival associated with different clinicopathological characteristics and treatment of patients with colorectal cancer.

  **Variables**            **Categories**         ***Crude***   ***Adjust 1[^\*^](#TN1){ref-type="table-fn"}***                                               
  ------------------------ ---------------------- ------------- ------------------------------------------------- ------------- ----------- ----------------- -------------
  Gender                   Male                   1             --                                                --            1           --                --
                           Female                 **0.77**      **0.61--0.97**                                    **0.031**     **0.73**    **0.57--0.93**    **0.011**
  Age at diagnose          \<50                   1             --                                                --            1           --                --
  (in years)               ≥50 to \<75            1.16          0.90--1.50                                        0.240         1.22        0.93--1.61        0.140
                           ≥75                    1.23          0.79--1.93                                        0.347         1.31        0.82--2.11        0.252
  Clinical stage (AJCC)    0/I                    1             --                                                --            1           --                --
                           II                     **2.68**      **1.40--5.14**                                    **0.003**     **3.22**    **1.58--6.58**    **0.001**
                           III                    **4.89**      **2.50--9.57**                                    **\<0.001**   **6.16**    **2.96--12.83**   **\<0.001**
                           IV                     **11.46**     **5.99--21.91**                                   **\<0.001**   **14.01**   **6.87--28.58**   **\<0.001**
  Histological type        Adenocarcinoma         1             --                                                --            1           --                --
                           Mucinous               0.58          0.33--1.04                                        0.070         0.53        0.28--1.00        0.051
                           Others                 1.13          0.33--3.82                                        0.840         1.04        0.30--3.61        0.947
  Histological grade       I/II                   1             --                                                --            1           --                --
                           III/Undifferentiated   1.13          0.74--1.72                                        0.552         **1.05**    **0.67--1.65**    **0.817**
  Lymphovascular           No                     1             --                                                --            1           --                --
  invasion                 Yes                    **1.55**      **1.17--2.04**                                    **0.002**     **1.53**    **1.15--2.04**    **0.003**
  Perineural invasion      No                     1             --                                                --            1           --                --
                           Yes                    1.17          0.88--1.56                                        0.264         1.12        0.83--1.51        0.454
  Presence of recurrence   No                     1             --                                                --            1           --                --
                           Yes                    **3.49**      **2.74--4.45**                                    **\<0.001**   **3.38**    **2.63--4.35**    **\<0.001**
  Treatment period         2000--2009             1             --                                                --            1           --                
                           2010--2014             0.98          0.75--1.28                                        0.898         0.92        0.69--1.22        0.572
  Surgery                  No                     1             --                                                --            1           --                --
                           Yes                    0.56          0.07--4.50                                        0.587         0.64        0.07--5.22        0.679
  Adjuvant chemotherapy    No                     1             --                                                --            1           --                --
                           Yes                    **0.58**      **0.42--0.79**                                    **0.001**     **0.55**    **0.40--0.76**    **\<0.001**
  Radiotherapy             No                     1             --                                                --            1           --                --
                           Yes, neoadjuvant       1.02          0.74--1.39                                        0.902         1.08        0.78--1.49        0.637
                           Yes, adjuvant          0.76          0.33--1.75                                        0.526         0.72        0.29--1.80        0.487
                           Yes, paliative         1.93          0.90--4.10                                        0.088         1.94        0.90--4.16        0.089

*Adjust 1: Genetic ancestry components by AIM-INDEL panel*.

*NA, Not available*.

*Significant associations are indicated in bold*.

Discussion {#s4}
==========

CRC is one of the most common neoplasms in men and women worldwide ([@B3], [@B30], [@B31]). Although its incidence is declining in the US and other western countries ([@B32]); in others, including Brazil, we are still witnessing an increase in the number of cases, and it is a major public health problem. In this study, we intended to characterize the genetic ancestry of an extensive series of 1,002 CRC patients admitted at the Barretos Cancer Hospital. Knowing that the Brazilian population is ethnically one of the most heterogeneous in the world ([@B14], [@B18]), with an essential contribution from the main ethnicities that formed the background of our population, we also intended to correlate the ancestry components (EUR, AFR, ASN, and AME) measured genetically with the different clinical--pathological factors and its prognostic role.

There was a slight male predominance, with an incidence of 1.08. In all regions of the world, despite the similarities between genders, the rates were higher for males (vs. females, 1.3) in the American population ([@B2], [@B33]), as well as in Europe ([@B1]) and Asia ([@B34]). Others have a higher incidence among women in the colon ([@B4], [@B35]).

The main studies divide the samples into three age categories: below 50, between 50 and 75, and above 75 years old. The age of 50 years old is critical to differentiate between hereditary and sporadic CRC cases. This age limit has been used in the Amsterdam criteria ([@B36], [@B37]) and also to recommend screening colonoscopic examination for people at average risk for CRC ([@B38], [@B39]). Although it has been reported that 21 to 33% of patients are older than 75 years \[Surveillance Epidemiologic and End Results (SEER)\] ([@B40]), they may account for more than 40% and are underrepresented in the clinical studies. These clinical studies use in their inclusion criteria an age group of up to 75 years old as a limit to be treated ([@B41]--[@B44]), mainly due to comorbidities. Therefore, we adopted the upper limit range as those with 75 or more years old ([@B45]).

The mean age at diagnosis in our population was 57.7 years (SD = 13.8), below the American age of 68 years ([@B31]) and the European age of 72 years ([@B45]). The predominant age group in our population was between 50 and 75 years old (60.5%), similar to that in the SEER ([@B31]) data.

Our population had a high incidence of patients younger than 50 years old (28.9%), higher than the 20% reported in studies including North American populations ([@B31]) and Asian patients (3--14%) ([@B46]). This finding can be due to the inclusion criteria and to the potential presence of some hereditary cases in the present analysis. In the present study, patients with a known and genetically confirmed familial history of Lynch or APC represented \<4% of cases ([@B21]); however, we cannot rule out the existence of hereditary cases in the cohort. Since 1992, the incidence in cases under 50 has increased by 1.5% per year ([@B3], [@B45]), especially from 20 to 34 years. According to the American College of Gastroenterology ([@B39]), colorectal cancer screening begins at age 50, except for those of African origin, where it is recommended to start at age 45 ([@B47]). Moreover, some studies even question to initiate at 40 years old ([@B48]). In concordance with these findings, we observed that Brazilian CRC patients depicting higher African proportion were associated with younger age of disease onset.

The importance of primary tumor location, being associated with distinct clinical--pathological features, as well as a differential prognostication has been widely discussed. For this, we performed the categorization of the cases included into the right colon, left colon, and rectum ([@B49]--[@B53]). In our population, 25% of the tumors were in the right colon. This percentage is within the average of other studies that ranged from 22.7 to 39% ([@B49]). However, in contrast, we did not find that laterality was associated with disease outcome.

Another critical variable is the TNM staging. In our study, the majority of cases were stage II (37.6%), followed by III (33.2%) and IV (16.7%). The percentage of stage IV at diagnosis is in agreement with several regions of the world ([@B31], [@B45], [@B54]).

Another goal of our study was to evaluate the main prognostic factors in our CRC patients. To this end, we estimated the OS and CSS and correlated with the different variables collected and selected in the multivariate analysis. The follow-up median of our sample was 62.0 months, very similar to the SEER that was 65.2 months ([@B31]). In the study of OS and CSS, we interrogated whether the variables selected in the multivariate analysis would be influenced by other variables such as the treatment period and the genetic ancestry components. Therefore, following adjustment of both variables, namely, treatment period (patients treated from 2000 to 2009 and from 2010 to 2014, where the introduction of the molecular target drugs, such as cetuximab, were included by the Department of Oncology of the Barretos Cancer Hospital), and ancestry, a multivariate analysis was performed.

The multivariate analysis for OS and CSS adjusted by genetic ancestry showed that the clinical stage, lymphovascular invasion, and recurrence of the disease were associated with an increased relative risk of death from cancer. In contrast, adjuvant chemotherapy was associated with a better outcome, as expected.

About 1/3 of our patients had lymphovascular invasion. The association of lymphovascular dissemination and adverse outcomes ([@B55], [@B56]) is well-described, besides being a known definer regarding therapeutics, especially in stage II ([@B3]).

The ancestry of the individuals assumes importance concerning its association with specific pathologies, immunological, and therapeutic responses, yet in the vast majority of studies, it is not evaluated ([@B57], [@B58]). Currently, with the availability of molecular tools for genetic studies, self-declaration and/or family origin can no longer be a proxy/authentication of the ancestral origin of an individual or population, especially in regions with a high degree of population admixture such as Brazil ([@B57]). However, in a large number of studies, skin color alone is used to assert ethnical origin of CRC patients ([@B7]--[@B9], [@B12], [@B59]). There is an extensive amount of studies, based on self-declaration, suggesting that black skin color patients have a higher incidence and lower survival of CRC ([@B7], [@B12]). However, it is unclear whether the ancestral component alone would influence survival or whether there are other confounding factors, such as less reference to screening methods ([@B60]), presence of a higher number of comorbidities diagnosis ([@B7]), lack of access to treatment services ([@B61]), or low educational/economic level, which can justify this fact ([@B11], [@B60]).

There are several ways to analyze the genetic composition of a particular population, and the selection criteria of genetic markers may diverge between studies, originating different values of the ethnic groups ([@B62]) for the Brazilian population. In our study, we analyzed four major ethnic compositions (EUR, AFR, ASN, and AME) using AIMs according to previous studies ([@B13], [@B14], [@B18], [@B63]). The present study was retrospective, dependent on the collection of information in medical records, and there was no mention of self-declaration of skin color. Therefore, our data collection instrument did not contemplate this aspect. If we had this information, we could have carried out a cross-referencing of information between the genotype and the phenotype to try to evaluate the fidelity of the latter.

When ancestry was measured genetically, we did not evaluate the data individually, but rather the four ancestor components that form the demographic base of Brazil. Our study did not intend to assess the causal relationship between genetic ancestry and CRC cancer as already done in other studies ([@B64]), but rather to correlate them with the various clinical--pathological characteristics of the patients.

As expected, the predominant ancestral component was the EUR one, with an average of 74% followed by the AFR with 13%, and by the ASN and AME with 7%, agreeing with previous studies of the Brazilian population ([@B13], [@B63], [@B65]). In agreement with other studies ([@B62]), a predominance of the European ancestral component in the Southeast and South regions was observed ([@B63]). Some differences in our study were observed, for example, the African component concentrated more strongly in the north region, unlike other studies based on the mitochondrial DNA (mtDNA) and not on autosomal AIM-*INDELs*, where this happened more in the Northeast Brazilian region ([@B13], [@B17], [@B62], [@B63]). The contribution of Asian ancestry in the northeast region of 5% is very close to that of the regions known to be colonized by Asians, but this may perhaps be explained first by the small sample size representing this region in our study and/or the proximity of the gene pool between Amerindians and eastern Asians considering the modern history of these human groups ([@B14]). The high SDs identified in our study show how miscegenated our Brazilian population is.

When we evaluated the individual components separately, we found that the European ancestral component was significantly associated with the absence of synchronous tumors. The African component was associated with younger patients, in agreement with other international studies ([@B7], [@B8], [@B10]). The Amerindian component predominated in the Northern region which correlates with other studies and is corroborated by the IBGE (Brazilian Institute of Geography and Statistics) self-declaration assessment ([@B13], [@B18], [@B63], [@B66]). Interestingly, we observed an association of the Amerindian component with mucinous histological type.

In our study, there was no correlation between the different ancestry proportions and patient survival. However, some North American studies reported an association of African ancestry based on self-declaration with tumors located in the right colon ([@B67]) and that these would be associated with more aggressive behavior histopathology, which would lead to worse survival ([@B7], [@B11], [@B12]).

Finally, despite the exciting and important findings, this study harbors some limitations, such as the retrospective nature of the study, based on the analysis of medical records, which often do not have complete and accurate information. The extent of the AIM panel could also be arguably higher. Nonetheless, the employed AIM indel set harbors a sufficient number of markers sparsely distributed throughout the genome and is simply analyzed in a multiplexed short-amplicon strategy, which are desirable characteristics considering the challenging nature of the source tumor samples included in our study. Despite the large number of patients and their diverse geographic origin, it does not represent all Brazilian states and the fully ethnical diversity of the Brazilian population, so further studies are warranted to extend our findings.

Conclusion {#s5}
==========

This pioneering work determined the genetic ancestry profile of more than 1,000 Brazilian patients diagnosed with CRC from a single oncology reference center. We described the main clinicopathological features of the population and observed that patients with a high African proportion develop cancer at a younger age. The present study can contribute to drawing a nationwide portrait of Brazilian CRC patient and may help in the design of management strategies for these patients.
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